Related Experiment Video
Updated: Mar 31, 2026
08:54
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
15.2K
Stereotactic Ablative Radiotherapy (SABR) in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer:
L Murray1, S Ramasamy1, J Lilley1
1St James's Institute of Oncology, Leeds Cancer Centre, Leeds, UK.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|October 18, 2015
Summary
Stereotactic ablative radiotherapy (SABR) is effective for early-stage peripheral lung cancer. This treatment offers good survival and local control with low toxicity for patients ineligible for surgery.
Area of Science:
- Oncology
- Radiotherapy
- Pulmonology
Background:
- Early-stage peripheral lung cancer often presents in patients unsuitable for surgery.
- Stereotactic ablative radiotherapy (SABR) has emerged as a promising alternative treatment modality.
Purpose of the Study:
- To evaluate the outcomes of the first UK cohort treated with SABR for early-stage peripheral lung cancer.
- To identify factors influencing overall survival and local control after SABR.
Main Methods:
- A review of electronic medical records for 273 patients who received SABR between May 2009 and May 2012.
- Univariate and multivariate Cox regression analysis to determine prognostic factors.
- Assessment of treatment adherence and toxicity according to Common Toxicity Criteria.
Main Results:
- The median overall survival was 27.3 months, with 3-year survival at 38.6%.
- High rates of local control were observed (98.2% at 1 year, 95.7% at 3 years).
- Medical Research Council breathlessness scores and histological diagnosis were significant predictors of overall survival; no factors influenced local control.
Conclusions:
- SABR is an effective and well-tolerated treatment for early-stage peripheral lung cancer in non-surgical candidates.
- The study supports the use of SABR for this patient population, adding to existing positive data.
- No patient subgroup was identified for whom SABR was deemed inappropriate.
